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Abstract
Tuberculosis  (Tb)  is  a  chronic  infectious  disease  in
which  the  cellular  immunity  (specifically  CD4+  and
CD8 lymphocytes) provides the most important de-
fense in controlling infection. CD4 lymphopenia is a
well-defined risk factor for the development of active
tuberculosis in patients infected with Human Immun-
odeficiency  Virus.  In  HIV  -  negative  patients,  CD4
and CD8 cell count suppression has been associated
with Tb infection. our study was designed to deter-
mine the baseline and post-treatment values of CD4
and CD8 in HIV negative patients diagnosed with ac-
tive Tb in saudi arabian patients. We recruited twenty-
eight,  non-HIV  patients  with  tuberculosis  for  the
study group comprising 16 males and 12 females with
either  disseminated  or  localized  active  Tb  infection.
Two control groups were selected – one of twenty-
one matched healthy controls and the second of forty-
two  subjects  from  pool  of  controls  of  an  ongoing
study in same population for normal CD4 and CD8
counts.  The  baseline  pre-treatment  CD4  and  CD8
counts in the study group were significantly lower than
either control group. specifically the mean ﾱ sD of
CD4 counts were 556.79 ﾱ 298.81 in the study group
vs 1,132.38 ﾱ 259.90 in control group 1 and 1,424.38
ﾱ 870.98 in control group 2 (p 0.000). Likewise the
CD8  counts  in  the  study  group  were  1,136.00  ﾱ
512.06 vs. 1,461.90 ﾱ 367.02 in control group 1 and
1,495.90 ﾱ 565.32 in control group 2 (p 0.000) respec-
tively. after treatment of tuberculosis, the study pa-
tients experienced a significant increase in their mean
ﾱ  sD  CD4  and  CD8  cell  counts,  from  556.79  ﾱ
297.81 to 954.29 ﾱ210.90 for CD4 cells (p 0.005) and
1136.00 ﾱ 512.06 to 1,316.54 ﾱ 286.17 for CD8 cells
(p 0.002). analysis of study patients with disseminated
disease found significantly lower CD4 cells (but not
lower CD8 cells) compared to study patients with lo-
calized disease, both at baseline and after treatment.
The  mean  ﾱ  sD  baseline  CD4  cells  were
247.60ﾱ187.80 with disseminated vs 728.56 ﾱ 186.32
for localized disease (p = 0.000) which rose to 842.30
ﾱ 93.55 vs 1016.50 ﾱ 233.51 (p = 0.033) respectively.
We conclude that tuberculosis may be associated with
CD4 and CD8 lymphopenia even in patients without
human  immunodeficiency  virus  infection,  there  was
the tendency of recovery towards normality especially
of the CD4 and CD8 counts after treatment, and that
disseminated  disease  is  associated  specifically  with
profound CD4 lymphopenia.
InTRoDuCTIon
Tuberculosis remains an infectious disease causing sig-
nificant morbidity and mortality on a global scale. The
fifteenth annual report of the World Health organiza-
tion [1] gave an estimate of the global burden of the
disease caused by Tb in 2009 as follows: 9.4 million
new cases, prevalent cases of 14 million and deaths of
1.3 million and 0.38 million among HIV-negative and
HIV positive people respectively.
The natural course of Tb infection is basically de-
termined by the ability of the host’s immune system
resulting  in  swift  eradication,  dormancy  or  failure,
which leads to active disease [2]. Protective immunity
to Tb in humans relies upon both CD4+ and CD8+
T-cells through cell-mediated responses, allowing full
eradication or control of infection [3]. The important
contribution of CD4+ T- cells is especially obvious in
HIV infection which by depletion of these subsets of
cells predisposes infected individuals to reactivation of
tuberculosis. It had previously been documented that
Tb infection itself may cause a CD4 lymphopenia in
patients not infected with HIV, sometimes with grave
consequences [4]. It had also been demonstrated that
the  CD4  lymphoenia  was  potentially  reversible  with
treatment [5]. The aim of this study was to determine
CD4  and  CD8  values  of  non-HIV  tuberculosis  pa-
tients at baseline and post treatment periods by flow
cytometry.
MaTERIaL anD METHoDs
We enrolled a study population of twenty-eight ran-
domly selected non- HIV infected patients with wide
spectrum  of  active  tuberculosis  seen  at  the  King
Khalid  university  Hospital  (KKuH),  Riyadh  over  a
one-year period. Eligible patients were enrolled based
on  compatible  symptoms  of  Tb  and  positive  My-
cobacterium tuberculosis based on Ziel -nielsen smear
and/or culture of relevant specimens as determined
by the bactec system and/ or Lowenstein-Jensen cul-
ture  methods.  The  first  control  group  of  matched
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by absence of history suggestive of tuberculosis, neg-
ative tuberculin tests and normal chest x-rays. The sec-
ond control group was derived from an ongoing study
determining  the  normal  range  of  CD4  and  CD8
counts from healthy controls of the same population
at KKuH. For this second control group, Quantiferon
negativity was additionally used to exclude latent tu-
berculosis. both subjects and controls were screened
for  HIV  and  were  ensured  negative  using  Enzyme-
linked  immunosorbent  assay  (ELIsa)  and  Recombi-
nant immunoblot assay (RIba). Patients and controls
were excluded if they have the following conditions:
any  form  of  immunodeficiency  syndromes,  diabetes
mellitus, chronic kidney disease and concurrent use of
immunosuppressant  medications.  Informed  consent
was sought from both subjects and controls before en-
rollment.  baseline  and  post-  treatment  CD4/CD8
counts in recruited patients and baseline parameters of
controls  were  recorded.  Patients  in  the  study  group
were  treated  for  two  months  with  isoniazid,  ri-
fampicin, pyrazinamide and ethambutol. The former
two drugs were then continued to complete treatment
of 6, 9, and 12 months for pulmonary, adenitis, and
military/disseminated/meningitis  respectively.  Cure
was determined by such parameters including resolu-
tion of fever, increase in weight, radiological resolu-
tion and decrease in erythrocytes sedimentation rate.
FLoW CyToMETRy sTuDy
blood  was  collected  in  EDTa  tubes  and  analyzed
within 6 hours of storage for direct immunofloures-
cence stain. Twenty (20) ul of fluorochromes conju-
gated  monoclonal  antibody  was  added  to  100ﾵl  of
whole  blood  in  Falcon  tube.  The  sample  was  then
spun gently and incubated for 15 minutes in dark at a
room temperature. The sample was further left for 10
minutes  after  adding  2  ml  of  FaCs  lysing  solution.
Centrifugation was done at 500 x g for 5 minutes fol-
lowed by discarding of the supernatant. The cells pel-
let was then re-suspended in 2 cc of wash buffer. Fur-
her  centrifugation  was  done  and  cells  were  re-sus-
pended in 0.5cc of paraformaldehyde for flow cyto-
metric  analysis.  acquisition  was  performed  on  FaC
scan  (becton  Dickinson  Immunocytometry  system).
CELL Quest software bDIs on list mode data was
then utilized to determine the lymphocyte gate by for-
ward  /  side  scatter  characteristic.  FLI/FL2  contour
plots were finally employed for two-color analysis.
Recorded data was analyzed using sPss version 16
statistical package. significance was determined at p
value of 0.05.
REsuLTs
Twenty-eight  patients  were  recruited  for  the  study
group, made up of 16 males and 12 females with a
combined mean age of 40 (Range 17-69) years. Table 1
shows the composite data of their total white blood
cells with mean+ sD of 9,653.6 ﾱ 5,602.3 (95% confi-
dence interval 7,436.5-11,900.4), lymphocytes 3,753.7
ﾱ 304.4 (2,549.4-4,958.0) and percentage lymphocytes
36.2  ﾱ  15.2  (30.2-42.2)  of  the  study  patients.  These
values were within normal reference values in our labo-
ratory. baseline meanﾱsD CD4 counts of study pa-
tients  (Table  2)  were  significantly  lower  at  556.79  ﾱ
297.81 versus 1132.38 ﾱ 259.90 in control group 1 and
1424.38 ﾱ 870.98 in control group 2 (pvalue 0.000).
Likewise, CD8 counts of study patients were signifi-
cantly lower as at 1136.00ﾱ 512.06 compared with ei-
ther  of  control  groups  at  1461.90  ﾱ  367.02  and
1495.90 ﾱ 565.32 respectively ( p value of 0.000). after
treatment, the study group experienced significant im-
provement in CD4 and CD8 counts. The meanﾱ sD
count of CD4 cells went up from 556.79 ﾱ 297.81 pre-
treatment up to 954.29 ﾱ 210.90 after (p 0.005), while
the CD8 cells were 1136.00ﾱ 512.06 and 1316.54 ﾱ
286.17 respectively (p 0.002). Patients with disseminat-
ed disease (miliary and localization in more than one
tissue)  showed  significantly  lower  initial  CD4  counts
(Table 3) than localized form (Pulmonary or adenitis),
with mean ﾱ sD CD4 counts of 247.60 ﾱ 187.80 ver-
sus 728.56 ﾱ 186.32 (p value 0.000). no significant dif-
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Table 1. Composite Data of Total White blood Cells (WbC), Lymphocytes and Percentage Lymphocytes among 28 patients of
the study group.
Parameter Total WBC Lymphocytes Percentage of Lymphocytes
Mean 9,652.6 3,753.7 36.2
standard Deviation 5,602.3 304.4 15.2
95% Confidence Interval 7,436.5-11,900.4 2,549.4-4,958.0 30.2-42.2
Table 2. Comparison of Pretreatment versus Controls and Post-treatment in CD4 and CD8 Counts 
CD4 Counts mean ﾱ SD p Value CD8 Counts mean ﾱ SD p Value
Pretreatment  556.79 ﾱ 297.81 0.000 Pretreatment 1136.00 ﾱ 512.06 0.000
Controls 1 1132.38 ﾱ 259.90 Controls 1 1461.90 ﾱ 367.02
Controls 2 1424.38 ﾱ 870.98 0.000 Controls 2 1495.90 ﾱ 565.32 0.000
Pretreatment  556.79 ﾱ 297.81 0.005 Pretreatment 1136.00 ﾱ 512.06 0.002
Post-treatment 954.29 ﾱ 210.90 Post-treatment 1316.54 ﾱ 286.17
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with disseminated and localized forms of the disease.
The post treatment value of CD4 counts in the dis-
seminated disease remained lower than localized dis-
ease  even  after  treatment  at  842.30  ﾱ  93.55  versus
1016.50 ﾱ 233.51 (p = 0.033).
DIsCussIon
Humans acquire infection with Mycobacterium tuber-
culosis (MTb) commonly by inhaling the bacterium.
only  a  small  number  of  bacilli  need  to  enter  distal
alveoli of the human’s lung to establish infection [6].
The alveolar macrophages form first line of defense
against the inhaled droplets containing MTb [7]. Cel-
lular-mediated immunity has a central role in the con-
tainment of Tb. The mechanism involves rapid onset
of Th1 cytokine response comprising interferon (IFn)
ʳ [8] and tumour necrosis factor (TnF)-ʱ [9]. Further-
more, restricted mycobacterial growth in the lungs had
recently  been  proposed  through  the  induction  of
Th17 cells leading to production of IL-17 and IL-23.
These cytokines cause inflammation and recruitment
of Th1 cytokine producing cells [10, 11]. CD8+ T-
cells had also been shown to be essential in effective
T-cell immune response [12].
The  majority  of  patients  successfully  contain  the
primary infection within 2-10 weeks and go on to de-
velop a vigorous delayed-type hypersensitivity (DTH)
response [2]. In most healthy adults, adaptive immuni-
ty mediated by T- cells controls (but does not eradi-
cate) Tb infection [13]. Thus ongoing protective im-
munity is required to maintain control over the bacilli.
Immune  failure  of  the  adaptive  immunity  results  in
clinical tuberculosis [14]. The HIV pandemic provides
direct evidence that loss of CD4 T-cell numbers and
functions resulted in progressive primary infection, re-
activation of endogenous Tb and enhanced suscepti-
bility to re-infection [15].
Many studies had documented low CD4 counts in
patients with tuberculous diseases, with few of them
showing the reversibility of the counts towards nor-
mality after treatment. similar to our study, uppal et al
[5] and Davoudi et al [16] found CD4 lymphopenia in
patients with tuberculosis. singhal and banavalikar [17]
also found low CD4 counts in both smear positive and
smear negative patients with pulmonary tu-berculosis.
In addition Kony et al [18] in a study in senegal found
extra-pulmonary and more especially miliary to have
substantially lower CD4 counts. This concurs with our
study  which  demonstrated  significantly  lower  CD4
counts in disseminated than localized disease. other
studies had inferred that patients with low CD4 counts
tend to have severe disease [19, 20] with profound in-
capacity.
Many hypotheses had been brought forward to ex-
plain the depletion of CD4+ which include unusual
response to infections and homing of lymphocytes to
affected tissue than in circulation [12]. similar to our
study, HIV- negative patients with Tb and CD4+ T-
lymphocyte depletion on presentation were shown to
normalize their CD4+ cell counts with Tb treatment
[21].  similarly,  bose  et  al  [22]  studied  21  cases  of
chronic,  multi-bacillary  pulmonary  Tb  refractory  to
treatment  and  found  that  the  decreased  mean
CD4/CD8  ratio  normalized  only  in  those  patients
who responded clinically and bacteriologically to ther-
apy; in refractory cases, the ratio remained low.
Reports  on  CD8  counts  in  HIV-negative  patients
with Tb had been conflicting. shijubo et al [23] found
significantly decreased CD8 cells, which is similar to
our finding of significantly lower CD8 in patients as
compared with controls. Davoudi et al [16] found low-
er number of CD8 cells in patients with severe disease
like meningitis/miliary forms of Tb as compared with
controls. The reversibility of CD4 lymphopenia with
successful  therapy  as  found  in  our  study  was  also
demonstrated in various studies [5, 21, 22].
In  conclusion,  our  study  found  significantly  lower
CD4 and CD8 counts among Tb infected HIV nega-
tive patients as compared with controls. The post-treat-
ment CD4 counts demonstrated the tendency towards
recovery to normal values. Patients with disseminated
disease  had  much  lower  CD4  values  than  localized
forms, with a delay of returning towards normality.
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